Want to join the conversation?
Specialty pharmaceutical company $ADMS said late-stage trial evaluating ADS-5102 (amantadine HCl) to treat levodopa-induced dyskinesia (LID) associated with Parkinson's disease met the study goals. Results from this randomized, placebo-controlled study showed statistically significant reduction in LID at 12 weeks for patients who received ADS-5102.
Late realization to $T that it cannot compete in the unlimited data market with its existing plans! Its newly launched plans seem more reasonable.
Wow, the new $HPE Pro x2 612 G2. Finally, a Surface Tab you can use for business!